<DOC>
	<DOCNO>NCT00104065</DOCNO>
	<brief_summary>CG53135-05 , recombinant human fibroblast growth factor-20 ( rhFGF-20 ) protein , investigation prevention oral mucositis . Oral mucositis commonly occur side effect high-dose chemotherapy patient undergo autologous hematopoietic stem cell transplant . The objective Phase II trial evaluate safety efficacy CG53135-05 administer single dose patient risk develop oral mucositis .</brief_summary>
	<brief_title>Safety Efficacy CG53135-05 Prevention Oral Mucositis Patients Receiving Bone Marrow Transplant</brief_title>
	<detailed_description />
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Male female patient age &gt; 18 yr Patients undergoing high dose chemotherapy without radiation therapy treatment condition autologous hematopoietic stem cell transplantation . The conditioning regimens include least one following : high dose melphalan ( Mel 200 ) , busulfan , etoposide , without total body irradiation . Patients Karnofsky performance score &gt; = 70 % Informed consent participation study Patients weigh &lt; 33 kg Premenopausal female patient pregnant , lactate likely become pregnant Patients active medical condition preclude autologous hematopoietic stem cell transplantation Patients diagnose active acquired immunodeficiency syndrome ( AIDS ) Hepatitis B/C Patients known hypersensitivity recombinant protein therapeutic Patients take CG5313505 , palifermin investigational drug past 30 day Patients untreated symptomatic dental infection Patients history sensitivity allergy E. coliderived product Patients WHO Grade 3 4 oral mucositis ( OM )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>oral mucositis</keyword>
	<keyword>oncology - supportive care</keyword>
	<keyword>mouth disease</keyword>
</DOC>